Mednet Logo
HomeGynecologic OncologyQuestion

How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy?

4 Answers
Mednet Member
Mednet Member
Radiation Oncology · Varian Medical Systems/Allegheny health network

Ling et al., PMID 30600093 -

The paper gives our philosophy in this scenario. The total dose is the function of dose to target and cumulative dose to rectum and bladder. To be able to give a higher dose with brachy, generally would favor around 30.6 Gy with EBRT and then limit the last 14.4 Gy to the...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Willis-Knighton Medical Center

We have no data suggesting a long-term cure with immunotherapy.

In this unfortunate situation, I would be comfortable going well beyond traditional tolerances. The patient has already locally failed one course of brachytherapy and a lesser dose would unlikely be curative. I would deliver 45 to 50 gr...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Sunnybrook Health Sciences Centre

I agree with the answers above.

I would aim for an EQD2 of 65-70 Gy for this course for the primary tumor. However, would favor 45 Gy to the pelvic nodes.

I would recommend interstitial brachytherapy, especially if the recurrence is 3-4 cm. I often prescribe 6-6.5 Gy x3 fractions with brachytherapy.

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt-Ingram Cancer Center

To clarify the initial therapy/clinical scenario - a post-op cervical (not uterine) cancer had surgery and then VBT alone, no EBRT? I'm not entirely sure of the rationale behind that thought process as that would not be a routine clinical workflow. Obs or EBRT (or chemoRT) are the mainstays here aft...

Register or Sign In to see full answer

How would you manage a recurrent cervical cancer previously treated with vaginal cuff brachytherapy and has had a complete response to chemo-immunotherapy? | Mednet